Recent advances in the diagnosis and classification of inflammatory bowel disease.
The availability of an increasing number of inflammatory bowel disease (IBD)-specific serologic antibodies, the discovery of disease-susceptibility genes, the introduction of pharmacogenetic markers, and the recent application of wireless capsule enteroscopy to the evaluation of patients with IBD are providing new types of information that must be integrated with more traditional IBD paradigms. The challenge facing researchers and clinicians is to determine how to incorporate these potentially clinically relevant insights into our understanding of disease pathogenesis and to define the spectrum of potential applications to the management of patients with IBD. The ultimate diagnostic and predictive value of these tests will likely be optimized when they are applied in combination, rather than individually. As the clinical relevance of this expanding diagnostic armamentarium is defined, it is hoped that these tests will enable clinicians not only to diagnose IBD accurately but also to determine disease patterns prospectively, suggest prognoses, and allow for individualization of therapeutic regimens.
Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, 8631 West Third Street, Suite 245E, Los Angeles, CA 90048, USA. vasiliauskas@csmc.edu
Eric
E
Vasiliauskas
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D003093:Colitis, Ulcerative / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000276:immunology; D003424:Crohn Disease / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000276:immunology; D003937:Diagnosis, Differential; D016099:Endoscopy, Gastrointestinal; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D010641:Phenotype; D011379:Prognosis
D019268:Antibodies, Antineutrophil Cytoplasmic